Effect of Exercise on Patients With Claudication Undergoing Surgery

NCT ID: NCT01980602

Last Updated: 2013-11-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Title: How does exercise improve the calf muscle in patients with poor blood supply to their leg?

Purpose of the project: Patients with peripheral arterial disease have a poor blood supply to their lower leg. The reduced inflow prevents the leg from utilising nutrients and oxygen as easily as a healthy leg would. This causes pain when walking (intermittent claudication), which often occurs after a reproducible distance e.g. every 50 yards. These patients have a reduction in their quality of life as they feel embarrassed in social situations e.g. walking around town requires multiple breaks, so they tend to avoid this and isolate themselves more.

One treatment for claudication is exercising until the pain comes onÍž which most are reluctant to do. Walking up to three times a week for an hour, can double most people's walking distances, but doesn't always. The reason why some improve with exercise and others do not remains unknown.

This project will be the first randomised controlled trial of exercise in claudicants that focuses on the adaptations that occur in the muscle at a cellular level. We wish to compare muscle cells from a group that have exercised and group that have not. We will focus on the change in muscle cell size and function at present, and later progress to why and how this happens.

Methods: We will take measurements at the start of the study (baseline), after 6 weeks and then 3, 6 and 12 months. These measurements will be of a patient's fitness, actual walking distances and blood samples. At the time of surgery, muscle from the calf will be taken from the affected leg. This will be processed at the University's biomedical science department to look at the different types of muscle fibre and how efficiently they are working.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intermittent Claudication Peripheral Arterial Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Intermittent claudication endothelial function cardiopulmonary testing inflammation muscle architecture

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Supervised Exercise Program

Group Type EXPERIMENTAL

Supervised Exercise program

Intervention Type PROCEDURE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Supervised Exercise program

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Community dwelling older adults aged 45 and over
* Diagnosis of intermittent claudication - ABPI \< 0.9 with symptoms in keeping with intermittent claudication
* Undergoing surgery for claudication
* Ability to walk without assistance
* Healthy control patients who are undergoing varicose vein surgery

Exclusion Criteria

* Participants who are unable to provide informed consent
* Severe of acute cardiovascular, musculoskeletal or pulmonary illness
* Critical limb ischaemia
* Active treatment for cancer
* Rheumatoid arthritis or any patient receiving steroids or disease modifying Antirheumatic drugs (DMARDS)
* Failure to complete a CPET
Minimum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Hull

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Daniel Carradice

Academic Clinical Lecturer

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Romesh Sarvanandan, MBBS MRCS

Role: PRINCIPAL_INVESTIGATOR

Hull York Medical School/ University of Hull/ Hull and East Yorkshire NHS Trust

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hull Royal Infirmary

Hull, , United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Romesh Sarvanandan, MBBS MRCS

Role: CONTACT

Phone: 01482674643

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Romesh Sarvanandan, MBBS MRCS

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

11/YH/0210

Identifier Type: -

Identifier Source: org_study_id